ghk-cu/argireline/leuphasyl Wellness – ProMedicaMD and healthier after Consistent use GHK-Cu/Argireline/Leuphasyl Serum (0.2%/3%/3%) - 30mL

[DOI] [PMC free article] [PubMed] [Google Scholar] (13).Ellis CR

While not yet FDA-approved as a standalone agent, cagrilintide peptide therapy is being investigated for: Obesity treatment Metabolic syndrome management Adjunctive therapy for GLP-1 agonist non-responders Research in combination with emerging agents like retatrutide Note: As of 2025, cagrilintide is still considered a research compound in many jurisdictions

The thresholds of the BPC groups, except the morphine group, were normalized 7 days after incision

For consumers, that pricing premium is not always supported by the strength of the public clinical evidence

However, the penetration of BPC-157 and KPV through intact skin is uncertain, so topical use may not provide the full benefits of the blend